Ultrasound destruction LHRH targeted microbubbles combined paclitaxel on ovarian cancer proliferation and apoptosis and intracellular drug concentration

Objective Ultrasound destruct ovarian cancer targeted ultrasound contrast agent(OCTUCA),another name is liposome microbubbles(LM)adhere with LHRH,to study the effect of which synergia paclitaxel treatment on ovarian cancer cell line OVCAR3 inducing change of proliferation,apoptosis and intracellular drug concentration.Method Culturing OVCAR3 cell line in vitro,to determine the appropriate concentration of paclitaxel treatment on OVCAR3 in vitro by MTT assay.Then using OCTUCA,paclitaxel,paclitaxel synergia ultrasound,ultrasound destruction LM synergia paclitaxel,ultrasound destruction OCTUCA synergia paclitaxel treat OVCAR3,determining the rate of cell proliferation by MTT assay,the rate of cell apoptosis by flow cytometry(FCM)assay,and the intracellular drug concentration by high performance liquid chromatogram(HPLC)assay.Result The appropriate concentration of paclitaxel treatment on OVCAR3 in vitro is 10-6mol/L.The proliferation inhibition and apoptosis ratio of ultrasound destruction OCTUCA synergia paclitaxel were obviously higher than the group of OCTUCA,paclitaxel,paclitaxel synergia ultrasound,ultrasound destruction LM synergia paclitaxel(P0.05).The intracellular drug concentration of ultrasound destruction OCTUCA synergia paclitaxel was obviously higher than the group of paclitaxel,paclitaxel synergia ultrasound,ultrasound destruction LM synergia paclitaxel(P0.01).Conclusion Ultrasound destruction OCTUCA synergia paclitaxel treat OVCAR3 can cause intracellular drug concentration accrescence,proliferation inhibition and induce apoptosis.